Last reviewed · How we verify

NCT04183556

The Effect of Turmeric on New Onset Primary Dysmenorrhea

Completed NA Last updated 24 April 2020
What this trial tests

NA trial testing Naproxen in Primary Dysmenorrhea in 90 participants. Completed in 23 April 2020.

Timeline
15 November 2019
Primary endpoint
23 April 2020
23 April 2020

Quick facts

Lead sponsorBatman Training and Research Hospital
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingnone
Primary purposetreatment
Enrollment90
Start date15 November 2019
Primary completion23 April 2020
Estimated completion23 April 2020
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Batman Training and Research Hospital

Who can join

Adults 16 to 35, female only, with Primary Dysmenorrhea. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study was planned as 150 patients. Patients who met early-onset dysmenorrhea criteria and who met the inclusion criteria; 150 patients were divided into 2 equal groups, and NSAID during the menstrual cycle, nsai + turmeric 1 gr oral powder form treatment was planned to be started in the other group. The pain frequency and severity before and after treatment were evaluated by visual analog scale and the two groups were compared.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Naproxen

Trials testing the same drug.

Other recruiting trials for Primary Dysmenorrhea

Currently open trials in the same condition.

Other Batman Training and Research Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04183556.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing